Regeneron Pharmaceuticals (REGN) Share-based Compensation (2009 - 2026)

Regeneron Pharmaceuticals' Share-based Compensation history runs 18 years deep, the most recent figure standing at $257.4 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 0.66% year-over-year to $257.4 million; the TTM figure through Mar 2026 stood at $995.4 million (down 1.29% YoY), while the FY2025 annual figure was $993.7 million, up 1.11% from the prior year.
• Share-based Compensation was $257.4 million for Q1 2026 at Regeneron Pharmaceuticals, up from $249.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $304.4 million in Q4 2024 to a low of $159.8 million in Q2 2022.
• Historically, Share-based Compensation has averaged $226.1 million across 5 years, with a median of $232.0 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation soared 43.02% in 2023, then fell 18.1% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $232.0 million in 2022, then climbed by 3.62% to $240.4 million in 2023, then advanced by 26.62% to $304.4 million in 2024, then dropped by 18.1% to $249.3 million in 2025, then gained by 3.25% to $257.4 million in 2026.
• The last three Share-based Compensation figures came in at $257.4 million (Q1 2026), $249.3 million (Q4 2025), and $237.0 million (Q3 2025), per Business Quant data.